ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1679

Developing a Standardized Corticosteroid Dosing Regimen in Pediatric Proliferative Lupus Nephritis

Nathalie Chalhoub1, Kelly Rouster-Stevens2, Marisa Klein-Gitelman3, Karen Onel4, Beatrice Goilav5, Sonia Savani6, Natasha Ruth6, Tingting Qiu7, Najla Aljaberi8, Jianghong Deng9, Angela Merritt8, Benjamin Laskin10, Anna Carmela Sagcal-Gironella11, Stacy Ardoin12, Deborah Levy13, Scott Wenderfer14, Bin Huang7, Hermine I Brunner15 and LaUNCH Project Investigators16, 1The University of Cincinnati College of Medicine, Cincinnati, OH, 2Emory University/Children's Healthcare of Atlanta, Atlanta, GA, 3Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 4Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, 5The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, 6Medical University of South Carolina, Charleston, SC, 7Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 8Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9Beijing Children’s Hospital, Beijing, China (People's Republic), 10Children's Hospital of Philadelphia, Philadelphia, 11Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ, 12Nationwide Children's Hospital, Columbus, OH, 13Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 14Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, 15PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 16LUpus Nephritis and Cellcept precision dosing in cHildren (LaUNCH), Cincinnati, OH

Meeting: ACR Convergence 2020

Keywords: corticosteroids, Lupus nephritis, Pediatric rheumatology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2020

Session Title: Pediatric Rheumatology – Clinical Poster III: SLE, Vasculitis, & JDM

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Corticosteroids (CS) remain the mainstay of therapy for childhood-onset systemic lupus erythematosus (cSLE). However, widely accepted strategies for oral (PO) or intravenous (IV) CS dosing are lacking. We aimed to 1) develop a standardized CS dosing regimen (SSR) and 2) achieve consensus for this SSR among pediatric rheumatology and nephrology physicians treating cSLE, including lupus nephritis (LN).

Methods: Consensus formation techniques were used. A Delphi questionnaire was completed to select relevant covariates influencing CS dosing in LN (Step 1). Retrospective data from 147 children with proliferative LN at 8 major cSLE treatment sites in North America were used to generate Patient Profiles (PP) describing cSLE course at 2 subsequent visits (Step 2). PP were sent to 142 physicians experienced in cSLE to rate the course of LN and extrarenal disease and propose PO and IV CS dose adjustments (Step 3). Using PP data for which consensus was achieved, an SSR was developed (Step 4) and refined based on responses from another questionnaire and a focus group of experienced physicians (Step 5). Then, the SSR was validated (Step 6) using a second subset of PP describing disease course for up to 6 months since the time of initial kidney biopsy. Consensus was defined as agreement by majority ( >50%) of PP ratings (Step 3, Step 6).

Results: In Steps 1 and 3, 103 physicians answered Delphi questions and rated 353 PP (response rate: 73%). In Step 6, 18 physicians (mean 13.4 years of experience) were asked to review 33 PP each resulting in 564 PP ratings, of which 437 (77.5%) and 460 (81.6%) yielded consensus on PO and IV CS dosing respectively. PO and IV CS dosing depends on the patient’s weight, the course of extrarenal activity, measured by the extrarenal SLEDAI score (Figure 1d), and the course of LN, described by changes/status of 3 LN response variables (LN-RVs, Figure 1a-c). The SSR reflects dosing customs agreed upon by physicians. Table 1 summarizes the SSR with focus on 2 disease courses (1:stable extrarenal/various LN; 2:stable LN/various extrarenal), with permutations of extrarenal disease course (much worse, mild-moderately worse, active stable/improved, inactive) and LN course (flare, mild-moderately worse, active stable/improved/partial or complete renal remission). Doses of PO CS ≥ 40 mg are guided by LN course except in major extrarenal flares with potential organ damage. IV CS are used for worsening disease courses that fail to respond to PO CS of ≥ 40 mg up to 4 weeks (Table 1). Small decreases of PO CS occur even with stable LN or extrarenal activity. Complete renal remission allows more pronounced reduction of PO CS. Beyond 6 months post kidney biopsy (maintenance therapy), CS dosing is informed by the renal response during induction therapy, the course of LN, and extrarenal activity (Table 1).

Conclusion: The proposed standardized CS dosing regimen for LN in cSLE may be useful for clinical care and regulation of background CS use during clinical trials of new medications for cSLE.

Figure 1. Consensus definitions for assessing changes in lupus nephritis response variables (LN-RVs) and extrarenal (ER) disease activity between clinical encounters

Table 1. Corticosteroid (CS) use provided by the standardized CS dosing regimen (SSR)


Disclosure: N. Chalhoub, None; K. Rouster-Stevens, None; M. Klein-Gitelman, None; K. Onel, None; B. Goilav, None; S. Savani, None; N. Ruth, None; T. Qiu, None; N. Aljaberi, None; J. Deng, None; A. Merritt, None; B. Laskin, None; A. Sagcal-Gironella, None; S. Ardoin, None; D. Levy, None; S. Wenderfer, Bristol-Myers Squibb, 1; B. Huang, None; H. Brunner, Bristol-Myers Squibb, 2, 5, MedImmune, 2, Novartis, 2, 8, Pfizer Inc, 2, 5, AbbVie, 5, AstraZeneca-MedImmune, 5, Bayer, 5, Biocon, 5, Boehringer Ingelheim, 5, Janssen, 5, Eli Lilly, 5, R-Pharm, 5, Roche, 5, 8, Cincinnati Children’s Hospital Medical Center, 3, GlaxoSmithKline, 8; L. Project Investigators, None.

To cite this abstract in AMA style:

Chalhoub N, Rouster-Stevens K, Klein-Gitelman M, Onel K, Goilav B, Savani S, Ruth N, Qiu T, Aljaberi N, Deng J, Merritt A, Laskin B, Sagcal-Gironella A, Ardoin S, Levy D, Wenderfer S, Huang B, Brunner H, Project Investigators L. Developing a Standardized Corticosteroid Dosing Regimen in Pediatric Proliferative Lupus Nephritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/developing-a-standardized-corticosteroid-dosing-regimen-in-pediatric-proliferative-lupus-nephritis/. Accessed June 30, 2022.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/developing-a-standardized-corticosteroid-dosing-regimen-in-pediatric-proliferative-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies